Deborah D Ascheim1, Annetine C Gelijns2, Daniel Goldstein2, Lemuel A Moye2, Nicholas Smedira2, Sangjin Lee2, Charles T Klodell2, Anita Szady2, Michael K Parides2, Neal O Jeffries2, Donna Skerrett2, Doris A Taylor2, J Eduardo Rame2, Carmelo Milano2, Joseph G Rogers2, Janine Lynch2, Todd Dewey2, Eric Eichhorn2, Benjamin Sun2, David Feldman2, Robert Simari2, Patrick T O'Gara2, Wendy C Taddei-Peters2, Marissa A Miller2, Yoshifumi Naka2, Emilia Bagiella2, Eric A Rose2, Y Joseph Woo2. 1. From the Icahn School of Medicine at Mount Sinai, New York, NY (D.D.A., A.C.G., M.K.P., J.L., E.B., E.A.R.); Montefiore-Einstein Heart Center, Bronx, NY (D.G.); University of Texas, Houston (L.A.M.); Cleveland Clinic Foundation, Cleveland, OH (N.S., S.L.); University of Florida, Gainesville (C.T.K., A.S.); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (N.O.J., W.C.T.-P., M.A.M.); Mesoblast Inc, New York, NY (D.S.); Texas Heart Institute, Houston (D.A.T.); University of Pennsylvania, Philadelphia (J.E.R.); Duke University, Durham, NC (C.M., J.G.R.); Baylor Health Care System, Dallas, TX (T.D., E.E.); Minneapolis Heart Institute Foundation, Minneapolis, MN (B.S., D.F.); Mayo Clinic, Rochester, MN (R.S.); Brigham and Women's Hospital, Boston, MA (P.T.O.); Columbia University Medical Center, New York, NY (Y.N.); and Stanford University, Stanford, CA (Y.J.W.). deborah.ascheim@mssm.edu. 2. From the Icahn School of Medicine at Mount Sinai, New York, NY (D.D.A., A.C.G., M.K.P., J.L., E.B., E.A.R.); Montefiore-Einstein Heart Center, Bronx, NY (D.G.); University of Texas, Houston (L.A.M.); Cleveland Clinic Foundation, Cleveland, OH (N.S., S.L.); University of Florida, Gainesville (C.T.K., A.S.); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (N.O.J., W.C.T.-P., M.A.M.); Mesoblast Inc, New York, NY (D.S.); Texas Heart Institute, Houston (D.A.T.); University of Pennsylvania, Philadelphia (J.E.R.); Duke University, Durham, NC (C.M., J.G.R.); Baylor Health Care System, Dallas, TX (T.D., E.E.); Minneapolis Heart Institute Foundation, Minneapolis, MN (B.S., D.F.); Mayo Clinic, Rochester, MN (R.S.); Brigham and Women's Hospital, Boston, MA (P.T.O.); Columbia University Medical Center, New York, NY (Y.N.); and Stanford University, Stanford, CA (Y.J.W.).
Abstract
BACKGROUND:Allogeneic mesenchymal precursor cells (MPCs) injected during left ventricular assist device (LVAD) implantation may contribute to myocardial recovery. This trial explores the safety and efficacy of this strategy. METHODS AND RESULTS: In this multicenter, double-blind, sham-procedure controlled trial, 30 patients were randomized (2:1) to intramyocardial injection of 25 million MPCs or medium during LVAD implantation. The primary safety end point was incidence of infectious myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization (90 days after randomization). Key efficacy end points were functional status and ventricular function while temporarily weaned from LVAD support (90 days after randomization). Patients were followed up until transplant or 12 months after randomization, whichever came first. Mean age was 57.4 (±13.6) years, mean left ventricular ejection fraction was 18.1%, and 66.7% were destination therapy LVADs. No safety events were observed. Successful temporary LVAD weaning was achieved in 50% of MPC and 20% of control patients at 90 days (P=0.24); the posterior probability that MPCs increased the likelihood of successful weaning was 93%. At 90 days, 3 deaths (30%) occurred in control patients, and none occurred in MPC patients. Mean left ventricular ejection fraction after successful wean was 24.0% (MPC=10) and 22.5% (control=2; P=0.56). At 12 months, 30% of MPC patients and 40% of control patients were successfully temporarily weaned from LVAD support (P=0.69), and 6 deaths (30%) occurred in MPC patients. Donor-specific HLA sensitization developed in 2 MPC and 3 control patients and resolved by 12 months. CONCLUSIONS: In this preliminary trial, administration of MPCs appeared to be safe, and there was a potential signal of efficacy. Future studies will evaluate the potential for higher or additional doses to enhance the ability to wean LVAD recipients off support. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01442129.
RCT Entities:
BACKGROUND: Allogeneic mesenchymal precursor cells (MPCs) injected during left ventricular assist device (LVAD) implantation may contribute to myocardial recovery. This trial explores the safety and efficacy of this strategy. METHODS AND RESULTS: In this multicenter, double-blind, sham-procedure controlled trial, 30 patients were randomized (2:1) to intramyocardial injection of 25 million MPCs or medium during LVAD implantation. The primary safety end point was incidence of infectious myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization (90 days after randomization). Key efficacy end points were functional status and ventricular function while temporarily weaned from LVAD support (90 days after randomization). Patients were followed up until transplant or 12 months after randomization, whichever came first. Mean age was 57.4 (±13.6) years, mean left ventricular ejection fraction was 18.1%, and 66.7% were destination therapy LVADs. No safety events were observed. Successful temporary LVAD weaning was achieved in 50% of MPC and 20% of control patients at 90 days (P=0.24); the posterior probability that MPCs increased the likelihood of successful weaning was 93%. At 90 days, 3 deaths (30%) occurred in control patients, and none occurred in MPCpatients. Mean left ventricular ejection fraction after successful wean was 24.0% (MPC=10) and 22.5% (control=2; P=0.56). At 12 months, 30% of MPCpatients and 40% of control patients were successfully temporarily weaned from LVAD support (P=0.69), and 6 deaths (30%) occurred in MPCpatients. Donor-specific HLA sensitization developed in 2 MPC and 3 control patients and resolved by 12 months. CONCLUSIONS: In this preliminary trial, administration of MPCs appeared to be safe, and there was a potential signal of efficacy. Future studies will evaluate the potential for higher or additional doses to enhance the ability to wean LVAD recipients off support. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01442129.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: Robert S George; Magdi H Yacoub; Giordano Tasca; Carole Webb; Christopher T Bowles; Patrick Tansley; James P Hardy; Gilles Dreyfus; Asghar Khaghani; Emma J Birks Journal: J Heart Lung Transplant Date: 2007-10 Impact factor: 10.247
Authors: Larry O Thompson; Christian A Skrabal; Matthias Loebe; Javier A Lafuente; Rick R Roberts; Ahmet Akgul; Vonne Jones; Brian A Bruckner; Vinay Thohan; George P Noon; Keith A Youker Journal: J Surg Res Date: 2005-01 Impact factor: 2.192
Authors: Timothy P Martens; Fiona See; Michael D Schuster; Hugo P Sondermeijer; Marco M Hefti; Andrew Zannettino; Stan Gronthos; Tetsunori Seki; Silviu Itescu Journal: Nat Clin Pract Cardiovasc Med Date: 2006-03
Authors: Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier Journal: N Engl J Med Date: 2007-08-30 Impact factor: 91.245
Authors: Emma J Birks; Patrick D Tansley; James Hardy; Robert S George; Christopher T Bowles; Margaret Burke; Nicholas R Banner; Asghar Khaghani; Magdi H Yacoub Journal: N Engl J Med Date: 2006-11-02 Impact factor: 91.245
Authors: Makoto Natsumeda; Victoria Florea; Angela C Rieger; Bryon A Tompkins; Monisha N Banerjee; Samuel Golpanian; Julia Fritsch; Ana Marie Landin; Nilesh D Kashikar; Vasileios Karantalis; Viky Y Loescher; Kostas E Hatzistergos; Luiza Bagno; Cristina Sanina; Muzammil Mushtaq; Jose Rodriguez; Marcos Rosado; Ariel Wolf; Kevin Collon; Louis Vincent; Anthony J Kanelidis; Ivonne H Schulman; Raul Mitrani; Alan W Heldman; Wayne Balkan; Joshua M Hare Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: John W MacArthur; Andrew B Goldstone; Jeffrey E Cohen; William Hiesinger; Y Joseph Woo Journal: Eur J Cardiothorac Surg Date: 2016-09 Impact factor: 4.191
Authors: Joshua M Hare; Darcy L DiFede; Angela C Rieger; Victoria Florea; Ana M Landin; Jill El-Khorazaty; Aisha Khan; Muzammil Mushtaq; Maureen H Lowery; John J Byrnes; Robert C Hendel; Mauricio G Cohen; Carlos E Alfonso; Krystalenia Valasaki; Marietsy V Pujol; Samuel Golpanian; Eduard Ghersin; Joel E Fishman; Pradip Pattany; Samirah A Gomes; Cindy Delgado; Roberto Miki; Fouad Abuzeid; Mayra Vidro-Casiano; Courtney Premer; Audrey Medina; Valeria Porras; Konstantinos E Hatzistergos; Erica Anderson; Adam Mendizabal; Raul Mitrani; Alan W Heldman Journal: J Am Coll Cardiol Date: 2016-11-14 Impact factor: 24.094
Authors: Andrew B Goldstone; Cassandra E Burnett; Jeffery E Cohen; Michael J Paulsen; Anahita Eskandari; Bryan E Edwards; Arnar B Ingason; Amanda N Steele; Jay B Patel; John W MacArthur; Judith A Shizuru; Y Joseph Woo Journal: J Cardiovasc Transl Res Date: 2018-02-21 Impact factor: 4.132
Authors: Lei Cai; Ruby E Dewi; Andrew B Goldstone; Jeffrey E Cohen; Amanda N Steele; Y Joseph Woo; Sarah C Heilshorn Journal: Adv Healthc Mater Date: 2016-10-06 Impact factor: 9.933